Mestag Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
43
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$40M
- Investors
-
6
Mestag Therapeutics General Information
Description
Developer of a biotechnology research and development platform designed to offer therapeutics for the treatment of cancer and inflammatory diseases. The company's platform exploits emerging insights related to the role of activated fibroblast populations in disease for developing therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory diseases and cancer, enabling the medical industry to combat and cure rare and life-threatening diseases.
Contact Information
Website
www.mestagtherapeutics.comCorporate Office
- Chesterford Research Park, Little Chesterford
- Suites 15 Science Village
- Cambridge CB10 1XL
- England, United Kingdom
Corporate Office
- Chesterford Research Park, Little Chesterford
- Suites 15 Science Village
- Cambridge CB10 1XL
- England, United Kingdom
Mestag Therapeutics Timeline
Mestag Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 17-Mar-2026 | $40M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC | 14-Oct-2024 | Completed | Startup | |||
| 2. Grant | 28-Aug-2024 | $1.94M | $45.2M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 16-Jul-2021 | $45.2M | $45.2M | Completed | Pre-Clinical Trials |
Mestag Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series Seed Preferred | ||||||||
| Series Seed Preferred |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Mestag Therapeutics Comparisons
Industry
Financing
Details
Mestag Therapeutics Competitors (50)
One of Mestag Therapeutics’s 50 competitors is Xenetic Biosciences, a Corporation company based in Framingham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| XBiotech | Corporation | Austin, TX | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Artios | Venture Capital-Backed | Cambridge, United Kingdom |
Mestag Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mestag Therapeutics Patents
Mestag Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026150046-A1 | Combination therapy | Pending | 09-Jan-2025 | ||
| AU-2025221952-A1 | Binding constructs | Pending | 16-Feb-2024 | ||
| US-20260176336-A1 | Binding constructs | Pending | 16-Feb-2024 | ||
| WO-2025172587-A1 | Binding constructs | Pending | 16-Feb-2024 | ||
| WO-2025172588-A1 | Bispecific constructs directed against fap and ltbr | Pending | 16-Feb-2024 | C07K16/28 |
Mestag Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mestag Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innovate UK | Government | |||
| Forbion | Venture Capital | Minority | ||
| GV | Corporate Venture Capital | Minority | ||
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority | ||
| Northpond Ventures | Venture Capital | Minority |
Mestag Therapeutics FAQs
-
When was Mestag Therapeutics founded?
Mestag Therapeutics was founded in 2020.
-
Where is Mestag Therapeutics headquartered?
Mestag Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of Mestag Therapeutics?
Mestag Therapeutics has 43 total employees.
-
What industry is Mestag Therapeutics in?
Mestag Therapeutics’s primary industry is Drug Discovery.
-
Is Mestag Therapeutics a private or public company?
Mestag Therapeutics is a Private company.
-
What is Mestag Therapeutics’s current revenue?
The current revenue for Mestag Therapeutics is .
-
How much funding has Mestag Therapeutics raised over time?
Mestag Therapeutics has raised $88.7M.
-
Who are Mestag Therapeutics’s investors?
Innovate UK, Forbion, GV, Johnson & Johnson JJDC, and Northpond Ventures are 5 of 6 investors who have invested in Mestag Therapeutics.
-
Who are Mestag Therapeutics’s competitors?
Xenetic Biosciences, CytomX Therapeutics, XBiotech, Protagonist Therapeutics, and Artios are some of the 50 competitors of Mestag Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
